# GLPG3667 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/glpg3667

> GLPG3667, sponsored by Lakefront Biotherapeutics NV (LKFT): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | GLPG3667 |
| Codes | GLPG3667 |
| Sponsor | Lakefront Biotherapeutics NV (LKFT) https://sec-api.dev/companies/lkft/catalysts |
| Indications | [dermatomyositis](https://sec-api.dev/indications/dermatomyositis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Apr 2023: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-27, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0001558370-25-003806): "In April 2023, we announced that the first patient was dosed in GALARISSO, the Phase 2 study with GLPG3667 in DM patients." https://www.sec.gov/Archives/edgar/data/1421876/000155837025003806/glpg-20241231x20f.htm

### December 18, 2025: topline data readout

- Status: completed, met. Date confidence: exact. Stage: 2. Indication: dermatomyositis.
- First seen 2025-02-12, last confirmed 2026-03-30.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-130447): "corticosteroid, OLE: open-label extension, QD: once daily, R: randomization On December 18, 2025, we announced topline results from the GALARISSO study, which are summarized below: The GALARISSO DM study met its primary endpoint, showing that" https://www.sec.gov/Archives/edgar/data/1421876/000119312526130447/d54917dex993.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-163796): "Topline results from ongoing studies with GLPG3667 are expected during the first half of 2026." https://www.sec.gov/Archives/edgar/data/1421876/000119312525163796/d21959dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-067161): "Topline results for the entire GLPG3667 program are anticipated in the first half of 2026.Following the planned strategic reorganization as announced early this year, we are seeking potential partners to take over our small molecule assets, including GLPG3667 for SLE, DM, and other potential auto-immune indications." https://www.sec.gov/Archives/edgar/data/1421876/000119312525067161/d932288dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-067161): "Topline results for the entire GLPG3667 program in both SLE and DM are expected in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1421876/000119312525067161/d932288dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-067161): "Topline results for the entire GLPG3667 program are anticipated in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1421876/000119312525067161/d932288dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-025186): "Topline results for the entire GLPG3667 program are anticipated in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1421876/000119312525025186/d914617dex992.htm
- SEC Form 10-K (accession 0001558370-25-003806): "Topline results for the entire GLPG3667 program are anticipated in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1421876/000155837025003806/glpg-20241231x20f.htm
- SEC Form 10-K (accession 0001558370-25-003806): "Topline results for the entire GLPG3667 program in both SLE and DM are expected in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1421876/000155837025003806/glpg-20241231x20f.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-130447): "AT A GLANCE PIPELINE ACHIEVEMENTS Immunology In December 2025, Galapagos announced topline Phase 2 results for TYK2 inhibitor, GLPG3667, in patients with dermatomyositis (DM) and systemic lupus erythematosus (SLE), which are summarized as follows: The GALARISSO DM study met its primary endpoint, showing that GLPG3667, administered once daily at 150 mg (N=21) in addition to standard-of-care therapy, achieved a statistically significant clinical benefit in the Total Improvement Score (TIS)2 at Week 24 (p=0.0848; ä: 14.26), compared to placebo (N=19)." https://www.sec.gov/Archives/edgar/data/1421876/000119312526130447/d54917dex993.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-04-23, last confirmed 2025-04-23.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-002429): "As announced in January 2025, Galapagos is seeking partners to take over its small molecule research portfolio and GLPG3667, its oral TYK2 inhibitor currently in Phase 3-enabling studies for systemic lupus erythematosus (SLE) and dermatomyositis (DM), with topline data expected in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1421876/000117184325002429/exh_991.htm

## Same indication

- [LISRAYA™ (brepocitinib)](https://sec-api.dev/pdufa/brepocitinib) (ROIV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/glpg3667.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GLPG3667 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/glpg3667

```bibtex
@misc{secapidev_pdufa_glpg3667_20261116,
  title        = {GLPG3667 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/glpg3667}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_glpg3667_20261116","title":"GLPG3667 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/glpg3667","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
